Nicotinamide riboside,
does it really help with Increased NAD+ and healthy aging?
research showsNR has increased blood NAD+ or related metabolites in several randomized trials. However, outcomes closer to healthy aging, including cognition, physical function, and metabolic and vascular function, have been small, heterogeneous, and often null. Distinguishing biochemical target engagement from a clinical anti-aging effect results in an overall grade of C.
ads claimProduct descriptions may connect higher NAD+ with cellular rejuvenation, restored energy, slower aging, or longer healthspan. The most directly supported human outcome is a change in blood or cellular NAD-related metabolites.
Useful facts when choosing a product
- NR doses in clinical trials commonly range from 500 to 2,000 mg/day for weeks to months.
- Trials of NR alone are not interchangeable with trials combining NR and pterostilbene.
- Blood NAD+ is a biochemical surrogate and does not directly measure lifespan or disease-free survival.
- Short-term trials generally found acceptable tolerability, but long-term high-dose data remain limited.
What the research actually shows
The 2018 crossover RCT by Martens and colleagues gave 24 healthy middle-aged and older adults NR 500 mg twice daily for six weeks and confirmed an increase in whole-blood NAD+ metabolites, while most cardiovascular and physical-function findings were exploratory. The 2024 pilot RCT by Orr and colleagues found that 1 g/day increased blood NAD+ 2.6-fold in 20 adults with mild cognitive impairment but did not alter cognition. The 2026 systematic review by Gallagher and Emmanuel found consistent increases in NAD-related metabolites with NR and NMN across 33 human intervention studies, but healthspan-related outcomes were mixed or null.
Why this is classified as C (52)
Repeated RCTs and a systematic review support increased NAD+, but this is a surrogate and healthspan-related clinical outcomes are frequently heterogeneous or null. Under the rule that surrogate-only evidence does not receive B or higher, the rating is C with 52 points.
Counterpoint. The effect of NR alone on blood NAD+ has been replicated. This judgment does not extend that biochemical effect to delayed aging or longer lifespan.
Rejudgment record. Reassessment (cross-check reflected) — Higher blood NAD+ with NR is repeated across RCTs, but it is a surrogate and healthspan-related functional, cognitive, and metabolic outcomes are heterogeneous and often null, limiting the grade to C
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Increase in blood NAD+ (mechanistic surrogate) | C | This biochemical surrogate has been repeated in several RCTs. |
| Clinical effects on healthy aging and anti-aging | D | Null cognitive and functional RCT findings. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Martens CR et al. 2018 | Randomized double-blind placebo-controlled crossover trial | 6 | US NIH; study material from ChromaDex and disclosed author interests | Whole-blood NAD+ metabolites, blood pressure, arterial stiffness, and physical function | NAD+ metabolites increased, while clinical functional findings were limited and exploratory. | Key |
| Orr ME et al. 2024 | Randomized placebo-controlled pilot trial | 10 | US federal research support and supplied NR | Blood NAD+, cognition, cerebral blood flow, and physical function | Blood NAD+ increased 2.6-fold, but cognition did not change. | Key |
| Gallagher C, Emmanuel OO. 2026 | PRISMA-guided systematic review | 28 | Authors reported no relevant supplement interest | NAD target engagement and functional, metabolic, vascular, and healthspan markers | Target engagement with NR and NMN was consistent, but clinical effects were heterogeneous and often null. | Key |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-11).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none
Cite this verdict
[Chamgap] Nicotinamide riboside (NR) × Increased NAD+ and healthy aging — Evidence Grade C·52. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/antioxidant-aging/nicotinamide-riboside-nad-healthy-aging/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.